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Objective: To evaluate the levels of plasmatic and synovial Coll2-1, Coll2-1NO2 and myeloperoxidase
(MPO) in horses with osteochondral lesions of the tarsocrural joint and to investigate how these levels
relate to arthroscopic ﬁndings of inﬂammation and degeneration.
Materials and methods: Venous blood and synovial ﬂuid samples were collected from 63 horses presented
for arthroscopic removal of osteochondral fragments in the tarsocrural joint. Prior to removal of the
osteochondral fragment, an exploration of the joint was performed and an inﬂammatory and degener-
ative score was determined. The blood and synovial levels of Coll2-1, Coll2-1NO2 and MPO were also
measured. The effects of the arthroscopic evaluation (inﬂammatory and degenerative classes) on the
blood and synovial markers were evaluated using a linear model (GLM procedure), and correlations
between biochemical markers in the blood and synovial ﬂuid and the arthroscopic evaluation (inﬂam-
matory and degenerative classes) were established (Pearson’s correlations).
Results: Signiﬁcantly higher levels of Coll2-1 were detected in synovial ﬂuid of higher degenerative
classes. There was a signiﬁcant correlation between the degenerative score and the synovial levels of
Coll2-1 (r¼ 0.27). According to the logistic regression model, there was a signiﬁcant effect of the
degenerative class on synovial levels of Coll2-1.
Conclusions: Coll2-1 correlates well with the degenerative state of tarsocrural joints as evaluated by
arthroscopy. This marker can therefore be classiﬁed as a burden-of-disease marker in the assessment of
joint disease in horses.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
In young horses, osteochondral fragments resulting from one
of the disorders grouped under Developmental Orthopaedic
Diseases (DOD) are commonly found1. Many horses are therefore
subjected to radiological screening prior to the start of athleticto: D.R. Verwilghen, Equine
gricultural Sciences, Ulls väg
950.
enis.verwilghen@uds.slu.se
s Research Society International. Pactivity. However, cartilage lesion severity as determined by
radiography does not always correlate with arthroscopic or
necropsy ﬁndings2,3, particularly for cartilage lesions that can be
present without the involvement of the subchondral bone and
therefore not show up on radiographs. More recently, there has
been increased interest in biomarkers reﬂecting chondropathy in
equine medicine4e9. Particularly since the measurement of
biomarkers, reﬂecting cartilage breakdown, is a powerful tool for
investigating joint damage caused by disease or injury and may
indicate the presence of osteoarthritis (OA) before it is radiolog-
ically visible. Particularly in cases of osteochondrosis (OCD),
biomarkers may reveal that surgical intervention is needed at
young age or prior to the start of athletic activity. More accurateublished by Elsevier Ltd. All rights reserved.
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by magnetic resonance modalities10; however, economic and
physical constraints often limit the clinical use of this technique
in equine medicine, especially in the most affected tarsocrural
and femoropatellar joints. A good correlation between the
macroscopic and ultrasonographic appearance of the joint surface
has been reported11 for the metacarpophalangeal joint. Despite
this correlation, arthroscopy remains the joint evaluation
modality of choice and is considered as the gold standard7,
although the procedure is more invasive and expensive than
alternative methods.
As blood and synovial sampling is less invasive than arthros-
copy, plasmatic and synovial markers that show a good correlation
with arthroscopic ﬁndings could be helpful in identifying the need
for surgical intervention. This approach could also be valuable in
serially evaluating joint disease and monitoring the inﬂuence of
treatments.
Coll2-1 is a recently introduced marker of type II collagen
degradation used in both human and equine medicine9,12e14. This
marker is very speciﬁc for joint investigation, as Coll2-1 is only
found in the alpha1 chain of type II collagen and the alpha3 chain of
type XI collagen; both chains are very speciﬁc for cartilage14.
Measurement of Coll2-1 fragments could therefore be considered
a good marker of cartilage degradation.
Coll2-1NO2 is the nitrated form of Coll2-1 and was found to be
elevated in sera of human patients with knee OA15,16 and in
horses suffering from juvenile degenerative digital osteo-
arthropathy13. Nitrated peptides are speciﬁc markers for protein
oxidation by peroxynitrite (ONOO), an unstable oxidant formed
by the reaction of superoxide anion ðO2 Þ and nitric oxide ðNOÞ17.
In situations mimicking inﬂammatory joint diseases, NO and O2
are produced by a large number of cells, including macrophages,
neutrophils, synoviocytes and chondrocytes18e20. Cartilage
matrix components were shown to be nitrated in situ or in
synovial ﬂuid after which they are released into the blood-
stream21. More recently, other pathways of peptide nitration have
been suggested. MPO-catalysed tyrosine nitration is currently the
most frequently discussed alternative mechanism involved in this
process22e25.
Myeloperoxidase (MPO) is an enzyme speciﬁcally in neutro-
phils, which is released by these cells after stimulation during
inﬂammatory processes. In human medicine, MPO has been
measured as a marker of neutrophil activation and tissue inﬁltra-
tion in a broad variety of pathologies26, including OA27. Increased
MPO activity was also observed in antigen-induced arthritis in
guinea pigs and was attributed to neutrophils attracted to synovial
tissue28.
We recently reported levels of synovial Coll2-1, Coll2-1NO2 and
MPO in normal and OCD-affected tarsocrural joints in the horse29.
OCD-affected horses showed signiﬁcantly elevated synovial levels
of Coll2-1 compared to unaffected horses, indicating the presence
of cartilage degradation in these joints. Nevertheless, no relation-
ship between the levels of the biomarkers and lesion severity was
determined using a golden standard method as arthroscopy7.
Therefore, the objective of the present study was to evaluate the
levels of plasmatic and synovial Coll2-1, Coll2-1NO2 and MPO in
horses with osteochondral lesions of the tarsocrural joint and to
investigate how these levels relate to the arthroscopic ﬁndings of
synovial inﬂammation and cartilage degeneration. Furthermore,
the relationship between the plasmatic and synovial levels of the
markers was investigated. We hypothesised that the synovial levels
of these biomarkers could reﬂect the inﬂammatory and degenera-
tive state of the joint, as evaluated by arthroscopy. Moreover, we
hypothesised that a correlation existed between the synovial and
plasmatic levels of the biomarkers used.Materials and methods
Horses and samples
Venous blood samples from the jugular vein and synovial
samples the tarsocrural joint from 63 client-owned horses pre-
sented for arthroscopic removal of osteochondral fragments in the
tarsocrural joint were used. The presence of these osteochondral
fragments was established by radiography during a full screening
including phalanges, metacarpo/metatarso-phalangeal, tarsocrural
and femoropatellar joints. All horses were unilaterally affected and
no other joints underwent or required any arthroscopic explora-
tion. Samples were collected into tubes (Monovette, 9 ml, Sarstedt)
containing ethylenediaminetetraacetic acid (EDTA) (1.6 mg/ml
blood/synovia). Blood samples were drawn prior to the induction of
anaesthesia, and synovial samples from the affected tarsocrural
joint were obtained under aseptic conditions prior to distension of
the tarsocrural joint for arthroscopy. Because these samples would
otherwise have been taken but discarded during surgery, owner’s
consent was not obtained.
Samples were separated by centrifugation at 7000g for 10 min
at room temperature and were then aliquoted and frozen at 20C
within 60 min of sampling. Samples were only thawed immedi-
ately prior to assays.
Arthroscopy and score attribution
All horse operations were performed according to the owner’s
request and by the same surgeon (EE). A standard arthroscopic
approach to the tarsocrural joint was used as described previ-
ously30 using a 30 oblique 4-mm arthroscope. An exploration of
the dorsal aspect of the joint was performed prior to removal of the
osteochondral fragment, and an inﬂammatory and degenerative
score was immediately determined according to the following
criteria adapted from Gangl et al12 and Trumble et al31.
Inﬂammatory score
The following ﬁve parameters of synovial inﬂammation were
evaluated: hyperaemia, petechiation, thickening and increase in
villi density, formation of new types of villi and rice bodies, atrophy
and ﬂattening with ﬁbrin and adhesion formation. Inﬂammation
was subsequently graded as zero-absent, one-mild, two-moderate,
three-severe and extensive12,31. The sum of the ﬁve grades
comprised the inﬂammatory score (0e15).
Degenerative score
The cartilage damage was graded as zero-normal, one-swelling
and softening, two-superﬁcial ﬁbrillation, three-deep ﬁbrillation
down to the bone, and four-exposure of the subchondral bone12,32.
The extent of the lesions was graded as one-small, localised to the
fragment site, two-focalised in the area around the fragment site or
on other, separate sites, three-on the fragment site as well as on
other sites, and four-extensive, including large parts (>50%) of the
articular surface. The sum of the damage grade and the extent
grade comprised the degenerative score (0e8).
The horses were grouped into three classes for each class
according to the obtained scores. The inﬂammatory class: A¼ 0e4,
B¼ 5e8, C> 8. The degenerative class: A¼ 0e3, B¼ 4e5, C¼ 6e8.
MPO assay
The content of the aliquots was diluted 40 times in 20 mM
phosphate buffered saline (PBS) at pH 7.4 containing 5 g/L bovine
serum albumin (BSA) and 0.1% Tween-20. MPO was assayed with a
speciﬁc enzyme-linked immunosorbent assay (Equine MPO-ELISA
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a rabbit anti-MPO primary antibody and a guinea pig alkaline
phosphatase-conjugated anti-rabbit secondary antibody (both
polyclonal). Phosphatase activity was detected by incubation with
a 2.7 mM paranitrophenyl phosphate solution (phosphatase
substrate) at 37C for 30 min in the dark. The reaction was stopped
with 2.5 M NaOH, and the absorbance at 405 nmwas read with the
Multiscan Ascent.Coll2-1 and Coll2-1NO2 assays
The Coll2-1 and Coll2-1NO2 assays are competitive immuno-
assays previously described in detail by Deberg et al.14. Brieﬂy,
microplates were coated with 200 ml streptavidin (0.5 mg/ml) for
at least 48 h. After washing with wash buffer (Tris 25 mM, NaCl
50 mM, 0.2% Tween-20 pH 7.3), microtitre plates were subse-
quently blocked with 400 ml/well blocking buffer (1.5 mM KH2PO4,
8 mM Na2HPO4, 2 mM KCl, 138 mM NaCl, 0.5 BSA pH 7.4) over-
night at 4C. Coll2-1 and Coll2-1NO2 were conjugated to biotin.
After washing, 100 ml biotinylated peptides (2.5 ng/ml Coll 2-1 or
1.25 ng/ml Coll 2-1NO2) was added to each well of streptavidin-
coated plates and incubated for 2 h at room temperature. Fifty
microlitres of calibrators (synthetic peptide) or unknown samples
diluted eight-fold in dilution buffer (10 mM PBS, 138 mM NaCl, 7%
BSA, 0.1% Tween-20 pH 7.0 for the Coll 2-1 immunoassay and
50 mM Tris, 138 mM NaCl, 7% BSA, 0.1% Tween-20 pH 8.0 for the
Coll2-1NO2 immunoassay) were added to the wells, followed by
either 100 ml anti-Coll2-1 (1/40,000) or anti-Coll2-1NO2 antibody
(1/500,000) and incubated for 1 h at room temperature. The
antisera and secondary antibody were diluted in 10 mM PBS,
138 mM NaCl, 0.2% BSA, 0.1% Tween-20, pH 7.0 for the Coll2-1
immunoassay and 50 mM Tris, 138 mM NaCl, 0.2% BSA, 0.1%
Tween-20, pH 8.0 for the Coll2-1NO2 immunoassay. After washing,
100 ml peroxidase-conjugated goat anti-rabbit IgG (Biosource
Europe S.A., Nivelles, Belgium), diluted 1/5000 were incubated for
1 h at room temperature. After washing, 100 ml freshly prepared
enzyme substrate was added to each well, incubated for 15 min,
and then the reaction was stopped with 100 ml 4 M H3PO4. The
absorption was read with a microplate reader at 450 nm, corrected
for absorbance at 650 nm.Statistical analysis
All data were analysed using SAS commercial software (Statis-
tical Analysis System, SAS Institute GmbH Heidelberg, Germany).
The normal distribution of the data was checked using a univariate
procedure and log-transformed to obtain closer normal distribu-
tion if needed.
The arthroscopic data used for statistical analyses were
consolidated into the inﬂammatory and degenerative classes A, B
and C.
The ﬁxed effects of sex, age, weight and the arthroscopic eval-
uation (inﬂammatory and degenerative classes) on the blood and
synovial markers were evaluated using a linear model (GLM
procedure).Table I
Mean (SD) levels of Coll2-1, Coll2-1NO2 and MPO in the blood and synovial ﬂuid.
n¼ 63
Coll2-1 nM Coll2-1NO2 nM MPO ng/ml
Blood 724.86 157.46* 1.9 0.5* 913.07 1464.64*
Synovial ﬂuid 183.99 79.22 0.94 0.37 38.52 52.1
* Denotes a signiﬁcant difference between the blood and synovial ﬂuid (P 0.05).Correlations between biochemical markers in the blood and
synovial ﬂuid, the arthroscopic evaluation (inﬂammatory and
degenerative classes), weight and age were measured using Pear-
son’s correlations (Corr procedure).
Mean values of biochemical markers in the blood were
compared with those in the synovial ﬂuid using t-tests.
Finally, logistic regression models were created to evaluate the
effect of the biochemical markers on the probability of belonging to
one of the inﬂammatory and degenerative classes.
Signiﬁcance was set at P 0.05.Fig. 1. Box and wisker plot of (A) plasmatic Coll2-1 levels per degenerative class,
(B) synovial levels of Coll2-1 per degenerative class and (C) synovial levels of LogMPO
per degenerative class. Like letters represent no signiﬁcant difference.
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The mean age [standard deviation (SD)] of the horses was
3.5 2.04 years with a median of 3.14 years, and the mean weight
(SD) was 525 82 kg.
The mean (SD) levels of Coll2-1, Coll2-1NO2 and MPO in the
blood and synovia are presented in Table I. Fig. 1 represents a box
and wisker plot of the signiﬁcant ﬁndings: (A) plasmatic Coll2-1
levels per degenerative class, (B) synovial levels of Coll2-1 per
degenerative class and (C) synovial levels of LogMPO per degen-
erative class.
The mean (SD) levels of Coll2-1, Coll2-1NO2 and MPO per
degenerative and inﬂammatory class in the blood and synovial
ﬂuid, respectively, can be found in Tables II and III. Signiﬁcantly
higher levels of Coll2-1 were found in the blood of the degenerative
class C than in the degenerative classes A (P¼ 0.0062) and B
(P¼ 0.0105). Signiﬁcantly higher levels of Coll2-1 were found in the
synovial ﬂuid of the degenerative classes B (P¼ 0.0247) and C
(P¼ 0.0011) than in the synovial ﬂuid of the degenerative class A.
Signiﬁcantly higher levels of LogMPO were found in the synovial
ﬂuid of degenerative class A compared to B (P¼ 0.0014) and C
(P¼ 0.0027).
There was a signiﬁcant correlation between the inﬂammatory
and degenerative score (r¼ 0.49) and between the degenerative
score and the synovial levels of Coll2-1 (r¼ 0.27; P¼ 0.0288).
A signiﬁcant positive correlation between the levels of Coll2-1
and Coll2-1NO2 in the blood (r¼ 0.54) and synovial ﬂuid
(r¼ 0.76), respectively, was detected.
According to the logistic regression model, there was a signiﬁ-
cant effect of the degenerative class on synovial levels of Coll2-1.
The log-odd probability to belong to the degenerative class B
instead of degenerative class A increased by 0.017 for each
increasing unit of synovial Coll2-1.
Discussion
The evaluation of joint disease using the non-invasive assess-
ment of the concentration of biomarkers has been the focus of
many researchers in the past decades. However, as illustrated in
a recent review, most veterinary studies investigate cartilage
breakdown by detecting type II collagen fragments using theTable II
Distribution of the classes and mean (95% CI) blood levels of Coll2-1, Coll2-1NO2 and Lo
n Coll2-1 nM
Inﬂammatory class A 44 724.86 (684.47e765
Inﬂammatory class B 15 712.19 (629.05e795
Inﬂammatory class C 4 855.04 (655.38e105
Degenerative class A 24 696.45 (636.16e756
Degenerative class B 21 718.91 (659.65e778
Degenerative class C 18 791.77 (725.61e857
* Signiﬁcantly different from degenerative class A (P¼ 0.0062) and B (P¼ 0.0105).
Table III
Distribution of the classes and mean (95% CI) synovial levels of Coll2-1, Coll2-1NO2 and
n Coll2-1 nM
Inﬂammatory class A 44 183.99 (19.35e430.8
Inﬂammatory class B 15 207.64 (63.43e412.0
Inﬂammatory class C 4 194.29 (132.97e270
Degenerative class A 24 147.61 (19.35e297.9
Degenerative class B 21 207.54 (116.56e382
Degenerative class C 18 227.02 (63.43e430.8
* Signiﬁcantly different from degenerative class B (P¼ 0.0247) and C (P¼ 0.0011).
y Signiﬁcantly different from degenerative class B (P¼ 0.0014) and C (P¼ 0.0027).carboxy-terminal telopeptide of type II collagen 3/4-length frag-
ment (C2C) or the carboxy-terminal cross-linked telopeptide frag-
ment of type II collagen (CTXII) markers and not Coll2-134.
Nevertheless, when comparing the usefulness of both C2C and
Coll2-1 in healthy and osteoarthritic mice, it was concluded that
these markers give complementary rather than redundant infor-
mation on the in vivo catabolic state of the articular cartilage35,
indicating the supplementary potential of Coll2-1 in identifying
chondropathy.
In the present study, using arthroscopy as a gold standard
method7 for the detection of cartilaginous lesions, signiﬁcantly
higher levels of Coll2-1 were found in the synovial ﬂuid of equine
tarsocrural joints affected with OC that had higher degenerative
scores and a clear correlation between the degenerative class and
the levels of Coll2-1 in the synovial ﬂuid was identiﬁed. In addition,
the logistic regression model deﬁned synovial Coll2-1 as the most
signiﬁcant parameter to explain the degenerative score. A signiﬁ-
cantly increased probability to belong to a less favourable degen-
erative class was shown with each increasing unit of Coll2-1
present in the synovial ﬂuid. This ﬁnding coincides with ﬁndings
from human medicine, where Coll2-1 is recognised as a diagnostic,
prognostic and burden-of-diseasemarker in human OA36 according
to the Burden of Disease, Investigative, Prognostic, Efﬁcacy of
Intervention and Diagnostic (BIPED) classiﬁcation38. In a compa-
rable study using C2C and CPII collagen particles and an arthro-
scopic grading system, biomarkers did not consistently reﬂect the
state of the joints37. When investigating C2C concentrations in
synovial ﬂuid of OCD-affected tarsocrural joints, de Grauw4 could
not ﬁnd any signiﬁcant difference from the controls. This mean that
Coll2-1 may be an earlier and more sensitive marker than C2C in
the detection of degenerative cartilage lesions in equids29. This
information underscores the diagnostic value of the marker or its
ability to classify individuals as either diseased or non-diseased38.
Considering these results, Coll2-1 could be given the title of diag-
nostic and burden-of-disease marker for joint disease in equids, as
is the case in humans.
In this study, both synovial and plasmatic levels of Coll2-1 were
measured, and plasmatic levels of Coll2-1 seem to be at least four-
fold greater than that of the synovial levels. Both synovial and
plasmatic values however remained in the same range as in
previous studies using horses of the same age range9,29. The higherg MPO per inﬂammatory and degenerative class. n¼ 63
Coll2-1NO2 nM Log MPO ng/ml
.25) 1.91 (1.78e2.03) 5.89 (5.57e6.23)
.33) 1.92 (1.77e2.07 6.30 (5.74e6.86)
4.70) 2.15 (1.93e2.37) 4.93 (4.19e5.67)
.75) 1.97 (1.79e2.14) 6.07 (4.05e8.82)
.17) 1.84 (1.72e1.96) 5.99 (4.04e8.51)
.93)* 1.96 (1.74e2.20) 5.67 (4.25e7.15)
Log MPO per inﬂammatory and degenerative class. n¼ 63
Coll2-1NO2 nM Log MPO ng/ml
8) 0.94 (0.38e2.08) 2.96 (0.11e6.46)
1) 0.99 (0.46e1.89) 2.25 (0.21e3.94)
.51) 0.77 (0.51e1.39) 2.66 (1.48e3.58)
6)* 0.83 (0.38e1.58) 3.45 (1.08e6.46)y
.79) 1.01 (0.50e2.08) 2.41 (0.78e4.95)
8) 1.01 (0.46e1.89) 2.29 (0.21e3.94)
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by an accumulation of collagen degradation particles diffusing from
several joints into the bloodstream. Since OA often affects more
than one joint it may produce higher circulating levels of collagen
degradation particles in the bloodstream than in an individual joint.
On the other hand, when joint pathology is sufﬁciently severe,
blood values of Coll2-1 may better reﬂect the severity of the
pathology. In fact, the serum levels of Coll2-1 predicted the
progression of radiographic knee OA15 and showed signiﬁcant
decline following knee prosthetic replacement in humans, which
provides evidence for the joint-speciﬁc nature of this marker27. This
hypothesis was reinforced by the higher levels of Coll2-1 found in
the degenerative class C, although the less severe classes A and B
did not show increased plasmatic levels.
Although Coll2-1NO2 is a marker that originates from degen-
erative cartilage particles, it is in essence a marker reﬂecting an
inﬂammatory state. Coll2-1NO2 was elevated in patients with
rheumatoid arthritis and correlates well with the levels of C-reac-
tive protein in the sera of these patients. Moreover, the ratio of
Coll2-1NO2/Coll2-1 in men can differentiate patients affected with
rheumatoid arthritis (RA) from those with OA14. In equids,
Coll2-1NO2 was elevated in the sera of Ardenner horses suffering
from juvenile degenerative digital osteoarthropathy (JDDO)13 and
was a potential indicator of the global osteoarticular status of the
animal9. In the present study, although positive correlations
between the levels of Coll2-1 and Coll2-1NO2 and higher Coll2-1
levels in the blood and synovial ﬂuid and between the inﬂamma-
tory and degenerative score were found, no difference in
Coll2-1NO2 could be identiﬁed based on arthroscopic evaluation.
Considering the low inﬂammatory status of the horses included in
this study (44/63 in inﬂammatory class A and only 4/63 in class C)
and the absence of variation between any of the markers with the
inﬂammatory grading used, Coll2-1NO2 may not be a very speciﬁc
marker to detect low inﬂammatory grade pathologies as occurs in
OCD compared to RA or JDDO. Moreover, no difference in the levels
of Coll2-1NO2 was found in the synovial ﬂuid of horses affected
with OCD of the tarsocrural joint compared to controls29, rein-
forcing this statement. Nevertheless, when compared to non-OCD-
affected controls, Coll2-1NO2 was previously shown to be elevated
in the sera of OCD-affected horses, but all horses included in that
study had clinical signs of joint effusion, positive ﬂexion tests and
lameness12.
MPO was also used as an inﬂammatory marker in this study.
However, no correlations between the levels of Coll2-1, Coll2-1NO2
and MPO could be established, either in the synovial ﬂuid or in the
blood. As MPO in the synovia of OCD-affected joints is not elevated
but does show signiﬁcantly higher levels in infectious arthritis39,
the expectations of MPO as a marker of low-grade inﬂammation
may have been an overestimation. The absence of differences in the
inﬂammatory markers used could also be the effect of clearance
from the joint. Myers et al40 showed that inﬂamed joints manifest
a signiﬁcant clearance of labelled proteins evenwith the occurrence
of mild synovitis. These data corroborate our detecting lower levels
of MPO in the B and C inﬂammatory classes, compared to class A.
Further, the reliability of scoring systems in the evaluation of the
degenerative status of joints has largely been validated32,41,42 since
its establishment by Beguin and Locker43. On the contrary, intra-
and inter-observer reliability of the qualitative method for synovial
inﬂammation evaluation has not yet been investigated, and
consistency in evaluating synovitis parameters by arthroscopy may
therefore be more difﬁcult to obtain44. To limit any variation, the
same experienced surgeon (E.E.) performed all horse surgeries.
Nevertheless, the absence of any correlation between the inﬂam-
matory markers and inﬂammatory scores could still be due to the
lack of reliability in evaluating synovitis.In conclusion, Coll2-1, a marker of type II cartilage degradation,
correlates well with the degenerative state of tarsocrural joints as
evaluated by arthroscopy. This marker can therefore be seen as
a burden-of-disease marker in the assessment or extent of joint
disease in horses. The use of Coll2-1 should therefore be considered
supplementary to the other synovial markers currently used in
equids.
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